潮州地区心脑血管病人群氯吡格雷基因多态性分析

摘要/Abstract

摘要： 目的为探究广东潮州地区心脑血管病患者中氯吡格雷相关基因细胞色素P450家族成员2C9（CYP2C19）的多态性位点分布详情。方法以2017年10月至2022年10月在该院就诊服用氯吡格雷的心脑血管病患者作为研究对象,采用RT-PCR对患者CYP2C19基因多态性位点进行检测并DNA测序验证,评估快、中、慢代谢基因型的频率以及等位基因的分布情况,同时对男性和女性的基因型频率差异进行比较分析。结果 621例心脑血管患者CYP2C19基因型频率分别为快代谢基因型（*1/*1）260例（41.87%）,中代谢基因型（*1/*2、*1/*3）267例（43.00%）,慢代谢基因型（*2/*2、*2/*3、*3/*3）94例（15.13%）,等位基因频率依次为CYP2C19*1（63.37%）,CYP2C19*2（30.68%）和CYP2C19*3（5.96%）。男、女患者CYP2C19基因型频率比较差异无统计学意义（P>0.05）。结论潮州地区心脑血管病患者氯吡格雷相关基因CYP2C19快代谢基因型和等位基因CYP2C19*1较国内其他地方略低,而慢代谢基因型和等位基因CYP2C19*3略高。CYP2C19基因型分布频率与性别无关。心脑血管患者进行氯吡格雷治疗前检测CYP2C19基因型,可指导临床制定合理安全的个体治疗方案。

关键词: 心脑血管, 氯吡格雷, CYP2C19, 潮州地区

Abstract: Objective To investigate the gene polymorphisms of clopidogrel-related cytochrome P450 family member 2C19 (CYP2C19) in patients with cardiovascular and cerebrovascular diseases in the Chaozhou region, China. Methods The patients with cardiovascular and cerebrovascular diseases who attended our hospital from October 2017 to October 2022 and were given oral administration of clopidogrel were enrolled as subjects in this study. RT-PCR was used to detect CYP2C19 gene polymorphisms, and DNA sequencing was used for validation. The distribution of genotype and allele frequencies was analyzed for patients categorized as extensive, moderate, and poor metabolizers, and the differences in genotype frequencies were compared between male and female patients. Results Among the 621 patients, there were 260 cases (41.87%) categorized as CYP2C19 extensive metabolizers (*1/*1), 267 cases (43.00%) categorized as moderate metabolizers (*1/*2, *1/*3), and 94 cases (15.13%) categorized as poor metabolizers (*2/*2, *2/*3, *3/*3), and the allele frequencies of CYP2C19*1, CYP2C19*2, and CYP2C19*3 were 63.37%, 30.68%, and 5.96%, respectively. There was no significant difference in the frequency of CYP2C19 genotypes between the male and female patients (P >0.05). Conclusion The prevalence rates of the extensive metabolism genotype of the clopidogrel-related CYP2C19 gene and CYP2C19*1 allele among patients with cardiovascular and cerebrovascular diseases in Chaozhou is slightly lower than those in other regions across China. The distribution of CYP2C19 genotype frequencies is not associated with sex. CYP2C19 genotype should be determined for patients with cardiovascular and cerebrovascular diseases before clopidogrel treatment, which can help to formulate reasonable and safe individualized treatment strategies in clinical practice.

Key words: Cardiovascular and cerebrovascular diseases, Clopidogrel, CYP2C19, Chaozhou region

程龙飞, 许嘉欣, 罗文虹, 林芬, 林旭城, 许伟. 潮州地区心脑血管病人群氯吡格雷基因多态性分析[J]. 心血管病防治知识, 2023, 13(24): 16-20.

CHENG Long-fei, XU Jia-xin, LUO Wen-hong, LIN Fen, LIN Xu-cheng, XU Wei. Clopidogrel gene polymorphism in patients with cardiovascular and cerebrovascular diseases in Chaozhou region, China[J]. Prevention and Treatment of Cardiovascular Disease, 2023, 13(24): 16-20.

参考文献

[1] Dansette PM, Rosi J, Bertho G, et al.Cytochromes P450 catalyze both steps of the major pathway of clopidogrelbioactivation,whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer[J]. ChemResToxicol, 2012,25(2):348-356.
[2] Karen L, Furie, Scott E, et al.Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association[J]. Stroke, 201,42(1):227-276.
[3] Ford NF.Clopidogrelresistance:pharmacokinetic or pharmacogenetic[J]. J Clin Pharm, 2009,49(5):506-512.
[4] Jiang XL, Samant S, Lesko LJ, et al.Clinical pharmacokinetics and pharmacodynamics of clopidogrel[J]. Clin Pharmaco, 2015,54(2):147-166.
[5] Shuldiner AR, O’connell JR, Bliden KP, et al.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J]. Jama, 2009,302(8):849-857.
[6] Mega JL, Close SL, Wiviott SD, et al.Cytochrome p-450 polymorphisms and response to clopidogrel[J]. N Engl J Med, 2009,360(4):354-362.
[7] 姬婧. 人CYP2C19和CYP2D6新变异体的体外酶活研究及CYP2C19等位基因分型[D].西北大学,2010.
[8] Frere C, Cuisset T, Gaborit B, et al.The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome[J]. Journal of Thrombosis & Haemostasis, 2010,7(8):1409-1411.
[9] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会, 中国循环杂志编辑委员会. 急性心肌梗死诊断和治疗指南[J]. 中华心血管病杂志, 2001, 29(12):705-725.
[10] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51:666-682.
[11] Scott SA, Sangkuhl K, Stein CM, et al.Clinicalpharmacogenetics implementation consortium guidelines for CYP2C19 genotype andclopidogrel therapy: 2013 update[J]. Clin Pharmacol Ther, 2013,94(3):317-323.
[12] 中华医学会心血管病学分会介入心脏病学组.中国经皮冠状动脉介入治疗指南 2012[J].中华危重症医学杂志, 2012,5(3):169-180.
[13] Jr HD, Dehmer GJ, Kaul S, et al.ACCF/AHA clopidogrel clinical alert: approaches to the FDA"boxed warning" : a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovas[J]. J Am CollCardiol, 2010,56(4):321-341.
[14] Mizobe M, Hokimoto S, Akasaka T, et al.Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients[J]. Throm Res, 2014,134(1):72-77.
[15] Mega JL, Close SL, WIVIOTT SD, et al.Cytochrome p-450polymorphisms and response to clopidogrel[J]. N Engl J Med, 2009,360(4):354-362.
[16] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 非ST段抬高急性冠状动脉综合征诊断和治疗指南[J]. 中华心血管病杂志,2012,40(5):353-367.
[17] 华仙丽,梁爱芬,雷亚利,等.广东东莞地区心血管疾病CYP2C19基因多态性分析[J].国际检验医学杂志,2017,38(5):606-608.
[18] 徐韫健,王慧,宋金龙,等.性别对华南地区汉族人群细胞色素P450酶2C19基因遗传多态性的影响[J]. 山东医药,2013,53(12):63-65.
[19] 刘美玲,张东梅,罗娥.华南地区汉族人群心脑血管相关基因多态性分析[J]. 检验医学与临床, 2016,13(9):1169-1171.
[20] 韩瑞玲,李艳,吴薇.武汉地区冠心病患者氯吡格雷药物代谢相关基因CYP2C19的多态性分布分析[J]. 现代检验医学杂志, 2015, 30(3):21-23.